BIONTECH SE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.81 USD | +0.74% |
|
+0.38% | -17.75% |
| Apr. 15 | Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... |  |
| Apr. 15 | Market outlook is uncertain, but optimism prevails | |
Chart calendar BioNTech SE
1785ca63b05569b85a0e94e32.uLxH-Alpanr31VN8UwyRKoLvf7FSirqG8C6qjNFHxDU.08gDjV8-IBSekAUoYG_EXfeCOd89vsvTqFjrypwurxjL7hfIRRwQG5HhAg~835b4a9e67ddf5af3317ef52229a7ca8
Upcoming events on BioNTech SE
Past events on BioNTech SE
| 2024-04-07 | American Association for Cancer Research Meeting - Poster Number CT165 |
| 2024-04-07 | American Association for Cancer Research Meeting - Poster Number CT051 |
| 2024-04-07 06:00 pm | American Association for Cancer Research Meeting - Abstract No: CT025 |
| 2024-03-20 08:00 am | Q4 2023 Earnings Call |
| 2024-03-20 06:15 am | Q4 2023 Earnings Release |
| 2024-03-10 | Leerink Partners Global Biopharma Conference |
| 2024-03-04 02:10 pm | TD Cowen Health Care Conference |
| 2024-02-26 | UBS European Healthcare Conference |
| 2024-02-12 | Oppenheimer Healthcare Life Sciences Conference |
| 2024-01-09 12:00 pm | JPMorgan Healthcare Conference |
| 2023-11-14 09:30 am | Jefferies London Healthcare Conference |
| 2023-11-07 09:00 am | Capital Markets Day - Innovation Series |
| 2023-11-06 08:00 am | Q3 2023 Earnings Call |
| 2023-11-06 06:45 am | Q3 2023 Earnings Release |
| 2023-11-03 | Society for Immunotherapy of Cancer Meeting - Abstract Number : 769 |
| 2023-11-03 06:30 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number : 599 |
| 2023-11-02 | Society for Immunotherapy of Cancer Meeting - Abstract Number : 597 |
| 2023-11-02 | Society for Immunotherapy of Cancer Meeting - Abstract Number : 813 |
| 2023-11-02 | Society for Immunotherapy of Cancer Meeting - Abstract Number : 1181 |
| 2023-10-23 10:30 am | European Society for Medical Oncology Congress - Abstract No LBA35 |
Past dividends on BioNTech SE
| 2022-06-01 | 1.549832 USD |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 109 110 -1.61% | 482 432 11.66% | 18 977 17 212 10.25% | 17 311 16 583 4.39% | 3 819 4 188 -8.8% | 2 794 |
|
EBITDA Million EUR | Released Forecast Spread | -148 -145 -1.86% | -43,7 -287 84.76% | 15 359 13 568 13.2% | 12 766 12 149 5.08% | 874 986 -11.36% | -639 |
|
EBIT Million EUR | Released Forecast Spread | -182 -167 -8.67% | -82,4 -306 73.08% | 15 284 13 364 14.37% | 12 643 11 959 5.72% | 690 866 -20.31% | -871 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -179 -158 -13.91% | -146 -325 55.09% | 15 046 13 109 14.78% | 12 954 12 372 4.7% | 1 186 1 270 -6.57% | -726 |
|
Net income Million EUR | Released Forecast Spread | -179 -157 -14.39% | 15,2 -336 104.53% | 10 293 9 140 12.6% | 9 434 8 838 6.75% | 930 1 070 -13.05% | -551 |
|
EPS EUR | Released Forecast Spread | -0,85 -0,74 -14.97% | 0,06 -1,44 104.17% | 39,6 36,2 9.36% | 37,8 35,2 7.41% | 3,83 4,45 -13.99% | -2,28 |
| Announcement Date | 31/03/20 | 30/03/21 | 30/03/22 | 27/03/23 | 20/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 5 533 3 918 41.19% | 6 375 4 496 41.77% | 3 197 4 109 -22.2% | 3 461 1 903 81.91% | 4 278 3 863 10.75% | 1 277 1 092 16.92% | 168 714 -76.53% | 895 775 15.45% | 1 479 1 850 -20.04% | 453 | 158 | 705 | 1 464 | 97,2 |
|
EBITDA Million EUR | Released Forecast Spread | 4 726 2 750 71.84% | 2 421 1 184 104.48% | 3 322 3 297 0.76% | 686 -160 528.63% | 114 -294 138.96% | 605 602 0.5% | -585 | -660 | -290 | 824 | ||||
|
EBIT Million EUR | Released Forecast Spread | 4 700 2 817 66.86% | 4 753 3 449 37.79% | 2 210 2 848 -22.42% | 2 388 1 295 84.34% | 3 293 2 543 29.5% | 654 226 189.21% | -563 -42,6 -1221.19% | 73,1 10,6 586.84% | 526 699 -24.69% | -374 | -637 | -246 | 295 | -804 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | 4 714 2 475 90.43% | 5 018 3 337 50.39% | 2 319 2 892 -19.82% | 2 444 1 426 71.38% | 3 173 2 658 19.38% | 708 200 253.56% | -412 378 -208.99% | 227 374 -39.15% | 663 773 -14.19% | -290 | -575 | -193 | 428 | |
|
Net income Million EUR | Released Forecast Spread | 3 166 1 893 67.22% | 3 699 2 484 48.92% | 1 672 2 056 -18.66% | 1 785 930 91.99% | 2 279 1 931 17.98% | 502 110 357.58% | -190 -3,99 -4675.04% | 161 -19,4 926.25% | 458 619 -26.07% | -264 | -527 | -178 | 398 | |
|
EPS EUR | Released Forecast Spread | 12,2 7,55 61.33% | 14,2 8,90 60.05% | 6,45 7,57 -14.81% | 6,98 4,86 43.48% | 9,26 8,07 14.75% | 2,05 0,57 258.03% | -0,79 -0,39 -102.27% | 0,67 -0,19 459.35% | 1,90 2,65 -28.18% | -1,07 | -1,92 | -0,75 | 1,28 | -1,50 |
| Announcement Date | 30/03/22 | 09/05/22 | 08/08/22 | 07/11/22 | 27/03/23 | 08/05/23 | 07/08/23 | 06/11/23 | 20/03/24 | - | - | - | - | - |
More events
Past sector events for BioNTech SE
| 2024-04-17 | BEIJING KAWIN TECHNOLOGY SHARE-HOLDING CO., LTD.: Q1 2024 Earnings Release (Projected) |
| 2024-04-17 | JIANGSU YAHONG MEDITECH CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-12 | SINOCELLTECH GROUP LIMITED: Q4 2023 Earnings Release |
| 2024-04-10 07:00 am | NURIX THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-04-08 | MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-02 03:06 am | TAIMED BIOLOGICS INC.: March 2024 Sales and Revenue Release |
| 2024-03-31 | PEPTRON, INC.: Q4 2023 Earnings Release (Projected) |
| 2024-03-31 | BIONEER CORPORATION: Q4 2023 Earnings Release (Projected) |
| 2024-03-29 08:30 am | INNOCARE PHARMA LIMITED: Q4 2023 Earnings Release |
| 2024-03-28 | BIO-THERA SOLUTIONS, LTD.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- BNTX Stock
- Calendar BioNTech SE
